Nexavar sorafenib regulatory update

BAY submitted an MAA to EMEA for Nexavar sorafenib to treat hepatocellular carcinoma (HCC). This summer, the companies plan to submit an sNDA to FDA for the multi-kinase inhibitor to treat HCC. Nexava...